|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the relationship between the 4G/5G polymorphism and plasma PAI-1 antigen levels in 104 Japanese males not taking lipid-lowering drugs and without non-insulin-dependent (type 2) diabetes mellitus or coronary artery disease.
|
10641442 |
1999 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to analyze the influence of the PAI-1 promoter 4G/5G genotype on PAI-1 levels in post-menopause women with coronary disease in comparison with healthy women in pre and postmenopausal status, and the influence of this genotype on variations in PAI-1 levels after hormone replacement therapy (HRT).
|
10235431 |
1999 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present data indicate that the 4G/4G genotype of the PAI-I gene polymorphism is an independent risk factor for coronary artery disease and that the additional presence of major cardiovascular risk factors accelerates the risk for this disease.
|
10494775 |
1999 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been shown to be an independent risk factor for coronary artery disease.
|
9812921 |
1998 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent evidence is accumulating that some clotting factors (fibrinogen, factor VII, von Willebrand factor) and fibrinolytic factors (t-PA and PAI-1) are associated with an increased risk of coronary artery disease.
|
9519344 |
1998 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased plasma plasminogen activator inhibitor-1 (PAI-1) concentration has been identified as a risk factor for coronary heart disease.
|
9445260 |
1998 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss two aspects of the molecular bases of CHD: i) Molecular bases of the candidate gene related to lipoprotein metabolism including apolipoprotein AI-CIII-AIV gene duster, apolipoprotein B, apolipoprotein E-CI-CII gene cluster, apolipoprotein(a), LDL receptors, lipoprotein lipase, cholesteryl ester transfer protein, and apo B editing protein; ii) Molecular bases of the candidate gene related to thrombotic and other factors including fibrinogen, factor VII, plasminogen activator inhibitor 1, homocysteine, stromelysin, paraoxonase, and angiotensin converting enzyme.
|
9539312 |
1998 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reduced fibrinolytic capacity due to increased plasminogen activator inhibitor-1 (PAI-1) activity in plasma is a common finding in patients with coronary heart disease or venous thromboembolism, although its clinical significance is debated.
|
9569196 |
1998 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease.
|
9484978 |
1998 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An insertion or deletion (I/D) polymorphism in the angiotensin converting enzyme (ACE) gene and a 4/5-guanine tract polymorphism (4G/5G) in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene are associated with the plasma activities of these substances and with coronary heart disease.
|
9844142 |
1998 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results from these studies further suggest that individuals with this responsive 2/2 PAI-1 genotype may reflect the additional inherent potential for later HTG-VLDL- or Lp(a)-induced fibrinolytic dysfunction, resulting in the early initiation of thrombosis, atherogenesis, and coronary artery disease.
|
9409314 |
1997 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Circulating (PAI-1) levels are elevated in patients with coronary heart disease and may play an important role in the development of atherothrombosis.
|
9198234 |
1997 |
|
SERPINE1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several longitudinal cohort studies of patients with manifest coronary heart disease (CHD) have linked elevated plasma PAI-1 or tPA antigen concentrations to future cardiovascular events, particularly myocardial infarction.
|
8578529 |
1995 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
|
8560407 |
1995 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased plasminogen-activator inhibitor 1 (PAI-1) activity is a common finding in patients with coronary heart disease.
|
7892190 |
1995 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There were no differences in prevalence of CHD or levels of blood pressure, serum lipids, or plasminogen activator inhibitor-1 (PAI-1) activity between the three ACE genotypes.
|
8521557 |
1995 |
|
SERPINE1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Familial high PAI levels with concurrent hypofibrinolysis co-segregated with familial combined hyperlipidemia, both being independent risk factors for premature coronary heart disease.
|
8191398 |
1994 |
|
SERPINE1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a sample of both 83 healthy individuals and 105 young patients with coronary artery disease from Sweden, the frequency of the 4G allele is roughly 0.5, and those individuals homozygous for the 4G allele have higher levels of PAI-1 than those with other genotypes (29% higher).
|
1456879 |
1992 |